Protexi / Celloram - LARVOL DELTA

Engineering durable tumor immunity with a virus-tumor hybrid antigen dendritic cell vaccine (AACR 2026) - "Combination therapy with either anti-PD-1 immune checkpoint blockade or the ALK5 (TGF-β type I receptor) inhibitor Vactosertib further augmented therapeutic efficacy in therapy-resistant tumor models. Collectively, these findings highlight the clinical potential of PROTEXI as an innovative DC vaccine platform that leverages the widespread prevalence of Spike-specific CD4⁺ T-cell immunity to enhance cancer vaccine efficacy—offering a promising therapeutic strategy for patients with advanced, immune-cold tumors."

IO biomarker • Oncology • CD4 • CD8 • CD80 • IL12A • PRAME • TGFB1 • TGFBR1